Skip to main content

Table 3 Summary of selected trials of stereotactic body radiation therapy for lung metastases

From: Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments

Study No patients Median dose/no fractions Median FU mos (range) Local control rate Overall survival Toxicity
Okunieff et al [13] 50 50 Gy/10 18.7 (3.7-60.9) 3-yr 91% 2-yr 50% G2 6.1%
48 Gy/6 G3 2%
57 Gy/3  
Norihisa et al [15] 34 48 Gy/4 27 (10-80) 2-yr 90% 2-yr 84% G2 12%
60 Gy/5 G3 3%
Le et al [14] 32 15 Gy/1 - 1-yr 54%   G2-G3 4
20 Gy/1 1-yr 54% G5 3
25 Gy/1 1-yr 91% Dose ≥ 25 Gy
30 Gy/1 1-yr 91%  
  2-yr 67%  
Salama et al [16] 61 24 Gy/3 20.9 (3-60.5) 1-yr 67.2% 2-yr 56.7% G3 3
48 Gy/3 2-yr 52.7%  
Rushoven et al [17] 38 60 Gy/3 15.4 (6-48) 2-yr 96% 2-yr 39% G3 3 (8%)
Ricardi et al [18] 61 45 Gy/3 20.4 (3-77) 2-yr 89% 2-yr 66.5% G3 1 (1.6%)
   26 Gy/1